Spyre Therapeutics, Inc. — Director's Dealing 2016

May 19, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2016-05-17

Reporting Person: Mahatme Sandesh (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-05-17	Director Stock Option (right to buy)	$7.28	A	10000	Acquired	2026-05-16	Common Stock (10000)	Direct

Footnotes

F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on June 17, 2016, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.